MECP2 and Rett syndrome: Advances in the understanding of the underlying pathophysiology have led to the development of new therapies, namely symptomatic pharmacologic interventions that act on the downstream cellular pathways affected in Rett syndrome, as well as gene therapy approaches that target the MECP2 gene directly.